BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valens Pharma Ltd. Announces Next Steps; Company Has Suspended Work on its DCA i.v Program


8/5/2008 3:00:17 PM

EDMONTON, Aug. 5 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced that the Company has suspended work on its DCA i.v program, a proprietary intravenous formulation of dichloroacetate pending further review by its Scientific Advisory Board. Based on the analysis of the voluntary Phase II "Mini-Metrxics" clinical trial by the Company's Scientific Advisory Board to date, it is clear that Valens does not have sufficient evidence to quickly move into its planned Phase III METRxICS Trial as had been anticipated. As previously announced, while data from the Phase II trial met certain biochemical endpoints, the anticipated clinical signals of a reduction in time spent in the intensive care unit (ICU), a reduction in ventilator times and a reduction in hospital times were not present. While there were no deaths during the actual trial in this high risk geriatric population, there were more adverse events in the group that received DCA compared to the control group. Requests for further information may be directed to the Company.

Read at Canada NewsWire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES